We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Biopharma Credit Plc | LSE:BPCR | London | Ordinary Share | GB00BDGKMY29 | ORD USD0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.002 | -0.23% | 0.876 | 0.874 | 0.878 | 0.878 | 0.874 | 0.878 | 1,220,548 | 11:38:04 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 135.74M | 108.45M | 0.0833 | 10.56 | 1.15B |
From Apr 2019 to Apr 2024
TIDMBPCR
RNS Number : 3026P
BioPharma Credit PLC
17 February 2021
17 February 2021
BIOPHARMA CREDIT PLC
(the "Company")
NOTICE OF FULL YEAR RESULTS
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, will announce its audited Full Year Results for the period ending 31 December 2020 on Tuesday 16 March 2021.
A management presentation will be delivered at 2:00pm GMT through a conference call facility. To request conference call details, RSVP to henryw@buchanan.uk.com .
-Ends-
Enquiries
BioPharma Credit PLC
via Link Company Matters Limited
Company Secretary
+44 (0) 1392 477 500
Buchanan
+44 (0)20 7466 5000
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORGPUACPUPGGQQ
(END) Dow Jones Newswires
February 17, 2021 02:00 ET (07:00 GMT)
1 Year Biopharma Credit Chart |
1 Month Biopharma Credit Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
